• XIIlab filed a correction to its March 26, 2025 stock option grant report to reflect adjustments tied to a paid-in capital increase.
• Grant size revised to 64,636 common shares from 60,000; exercise price reset to KRW 6,767 from KRW 7,290.
• Total outstanding, unexercised options after the grant updated to 231,210 common shares from 186,000.
• Recipient allocations were adjusted to 43,091 shares for Yun Se-hyeok and 21,545 shares for Chae Jeong-hwan.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. XIIlab Co. Ltd. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261007000480), on October 07, 2026, and is solely responsible for the information contained therein.